

A Study on the Development of First-in-class Myc Inhibitor Candidate for the Treatment of Solid Tumor and Hematologic Cancer



ONCOLOGY	Candidate
Product Type	Small molecule
Indication	Solid tumor/Hematologic cancer
Target	Myc (c-Myc/L-Myc/N-Myc)
MoA(Mechanism of Action)	Director Inhibitor that interferes with of Myc/Max complex binding to DNA
Competitiveness	<ul style="list-style-type: none"> • First -In-Class: Direct Myc Inhibitor • Direct Inhibitor: Overcomes the limitations of indirect inhibitors with narrow indications and weak pharmacological activity • High Selectivity: At least 100 times higher than other transcription factors and kinases/phosphatases • High Efficacy: High effectiveness of GI50 < 30 mg/kg level in PO/QD
Development Stage	Candidate
Route of Administration	Oral